Learnings from LANDMARK and Compare-TAVI at 3 years

At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.

LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At one year, outcomes confirmed the non-inferiority of the new platforms, in line with the reassuring 30-day results.

Compare-TAVI 1 evaluated Myval against the Sapien series over three years, showing that patients can be treated just as safely with this newer valve.

Combined data from both trials support the reliability of Myval in terms of composite endpoints.

The discussion also touched on the evolution of the device, its hemodynamic profile, and what this could mean for future TAVI strategies.

Watch the round table for an in-depth look at the data and what it means for daily practice.

This interview was filmed at EuroPCR 2025: see more videos here.